SLC5A2 and diabetes mellitus: Sodium-glucose transporter 2 (SGLT2) inhibitors are a novel class of oral therapeutic medications that have been approved for the treatment of type 2 diabetes mellitus by the Food and Drug Administration (FDA) (7).